Alexandria, VA and Peconic, NY, May 24, 2022 – The Schizophrenia & Psychosis Action Alliance (S&PAA) has formed a strategic collaboration with the Henry Amador Center on Anosognosia and the LEAP Institute to create The Anosognosia Coalition, whose goals are to raise insights into and awareness of the destructive condition of anosognosia and create policies to reduce its negative impact on people living with schizophrenia and psychosis disorders.
Anosognosia is a neurological symptom that prevents people living with schizophrenia and related brain diseases from understanding they have the disease. An estimated 57% to 98%1 of people living with schizophrenia experience anosognosia, which is the most common barrier2 to a person’s seeking what can be lifesaving medical care.
Anosognosia often causes a person with schizophrenia to refuse treatment, which can lead to severe negative health outcomes – including reducing a person’s life expectancy by an average of 28.5 years. Anosognosia also increases the risk of homelessness and arrest.3
“Anosognosia is a cruel condition that stands in the way of effectively treating schizophrenia and psychosis disorders,” said Dr. Xavier Amador, CEO of the Henry Amador Center on Anosognosia. “The more we understand it, the more successful we will be in overcoming its impact and getting people the treatment they need and deserve.”
The Anosognosia Coalition will work to increase awareness and understanding of the condition, to better inform policies and programs that can lead to more effective treatment and care for people living with schizophrenia.